Verve Therapeutics Announces Pipeline Progress and Reports Fourth Quarter and Full Year 2024 Financial Results
Provided By GlobeNewswire
Last update: Feb 27, 2025
Initial data from the Heart-2 Phase 1b clinical trial of VERVE-102 targeting PCSK9 expected in the second quarter of 2025, with final dose escalation data in the second half of 2025
Read more at globenewswire.com5.19
-0.31 (-5.64%)
Find more stocks in the Stock Screener
VERV Latest News and Analysis
18 days ago - ChartmillUnusual volume stocks are being observed in Tuesday's session.Let's have a look at what is happening on the US markets on Tuesday. Below you can find the stocks with an unusual volume in today's session.
18 days ago - ChartmillThe market is filled with gapping stocks in Tuesday's session.In today's session, there are notable price gaps in the US markets on Tuesday. Take a closer look at the stocks that are gap up and gap down.
19 days ago - ChartmillGapping stocks in Monday's sessionInvestors and traders are closely monitoring the gap up and gap down stocks in today's session on Monday. Let's explore the market movements and identify the stocks with significant gaps.
20 days ago - ChartmillThese stocks are moving in today's pre-market sessionThe US market is yet to commence its session on Monday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
